News and research.
Reify, SubjectWell partner to elevate trial recruitment
Outsourcing-Pharma.com
The Rise of Decentralized Clinical Trials Is Disrupting Traditional Patient Recruitment
Buzz about decentralized clinical trials (DCTs) and hybrid designs has been around for years; however, it took the in-person restrictions brought about by COVID-19 to accelerate...
Surprisingly, patients are more willing to participate in a COVID-19 vaccine trial as coronavirus vaccines become more widely available.
Marking more than a year since the pandemic began, the world has witnessed how essential clinical research is to creating safe, life-changing treatments. And, more specifically,...
Reify Health and SubjectWell Launch Partnership to Boost Patient Recruitment for Clinical Trials
AUSTIN, TX and BOSTON, MA, March 31, 2021 – Reify Health, provider of leading cloud-based solutions that empower the clinical trial ecosystem, and SubjectWell, the risk-free clinical...
Survey reveals thoughts on trial participation from patients at-risk for liver disease
Outsourcing-Pharma.com
As liver disease cases rise in the US, data shows that patients both at-risk and with a diagnosis of liver disease are willing to participate in clinical research.
Known as the silent liver disease, nonalcoholic fatty liver disease (NAFLD) affects between 30% and 40% of all adults in the US. Fatty liver disease (FLD)...
Concerns around clinical trial participation continue to differ by race.
Since the start of the pandemic, SubjectWell has kept a close eye on patient attitudes and feelings toward clinical trials. After all, right now is arguably...
SubjectWell and Reify Health Surveyed Clinical Trial Sites, Examined Patient Concerns and Site Safety Protocols in the Face of COVID-19
AUSTIN, TX and BOSTON, MA, October 7, 2020 – SubjectWell, the risk-free clinical trials marketplace, and Reify Health, provider of leading cloud-based solutions that empower the clinical...
SubjectWell eyes diversity in COVID-19 vaccine trials
Outsourcing-Pharma.com
SubjectWell Recruits Patients for COVID-19 Vaccine Clinical Trials, Works to Address Lack of Racial Diversity in Patient Recruitment To Date
Austin, TX, August 25, 2020 – SubjectWell, the largest risk-free clinical trials marketplace, announced today it is working with leading pharmaceutical companies to recruit patients for Phase...
Race and gender play a role in patient sentiment toward clinical research during the COVID-19 pandemic.
At SubjectWell, we continue to conduct surveys with patients to understand how their attitudes and feelings toward clinical trials have been altered in the wake of...
Registry connects COVID-19 trials with motivated patients
Outsourcing-Pharma.com
Patient attitudes toward clinical research continue to evolve during the COVID-19 pandemic.
At SubjectWell, we have been conducting an ongoing survey since the beginning of the pandemic to understand how patient attitudes toward clinical research participation have been...
SubjectWell Offers Registry of more than 10,000 Patients Willing to Participate in COVID-19 Research
Pharmaceutical Outsourcing
SubjectWell Offers Registry of Patients Willing to Participate in COVID-19 Research
Applied Clinical Trials
SubjectWell Offers Researchers Registry of 10K+ Patients Willing to Participate in COVID-19 Research
Austin, TX, May 13, 2020 – As the pharmaceutical industry mobilizes at unprecedented speed to develop a COVID-19 vaccine, SubjectWell, the world’s largest marketplace for clinical...
A growing number of patients are considering clinical trials as the coronavirus pandemic continues.
In our ongoing effort to both understand patients’ evolving attitudes toward clinical trial participation in the face of COVID-19 and support our industry’s continued commitment to...
Despite COVID-19, Patients Are Interested In New Trials
Clinical Leader
Data shows a majority of patients remain interested in clinical trials during the coronavirus pandemic.
The coronavirus pandemic has impacted clinical trial operations with unprecedented speed and severity. In order to gauge how the industry and the public are responding, our...